Substance

ID:839

Names and Identifiers
Brand Name
CarbocainCarbocaineIsocaine HCLScandicainPolocaine-MPFArestocaine HCLScandicainePolocaineScandicaneScandonest Plain
IUPAC name
N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
Synonyms
DL-MepivacaineMepivacainum [INN-Latin]Mepivacaine HCLmepivacaine hydrochlorideMepivacaineMepivicaineS-Ropivacaine MesylateMepivacaina [INN-Spanish]
IUPAC Traditional name
mepivacaine
Registration numbers
PubChem CID
CAS Number
PubChem SID
Properties
Physical Property
Hydrophobicity(logP)
2.2
Solubility
Soluble (7000 mg/L)
Molecule Details
Drug Groups
approved
Description
A local anesthetic that is chemically related to bupivacaine but pharmacologically related to lidocaine. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168)
Indication
For production of local or regional analgesia and anesthesia by local infiltration, peripheral nerve block techniques, and central neural techniques including epidural and caudal blocks.
Pharmacology
Mepivicaine is a local anesthetic of the amide type. Mepivicaine as a reasonably rapid onset and medium duration and is known by the proprietary names as Carbocaine and Polocaine. Mepivicaine is used in local infiltration and regional anesthesia. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal.
Toxicity
The mean seizure dosage of mepivacaine in rhesus monkeys was found to be 18.8 mg/kg with mean arterial plasma concentration of 24.4 µg/mL. The intravenous and subcutaneous LD 50 in mice is 23 mg/kg to 35 mg/kg and 280 mg/kg respectively.
Affected Organisms
Humans and other mammals
Biotransformation
Rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine. The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
Absorption
Absorbed locally. The rate of systemic absorption of local anesthetics is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution.
Half Life
The half-life of mepivacaine in adults is 1.9 to 3.2 hours and in neonates 8.7 to 9 hours.
Protein Binding
Mepivacaine is approximately 75% bound to plasma proteins. Generally, the lower the plasma concentration of drug, the higher the percentage of drug bound to plasma.
Elimination
It is rapidly metabolized, with only a small percentage of the anesthetic (5 percent to 10 percent) being excreted unchanged in the urine.The liver is the principal site of metabolism, with over 50% of the administered dose being excreted into the bile as metabolites.
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data